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for a mean follow-up of 81.4 months. The 3 patients who 
died due to breast carcinoma showed fine pleomorphic 
calcifications, and had nodal-positive invasive carcinoma 
at diagnosis. Conclusion: Microcalcification-associated 
breast cancers are frequently treated with breast-con-
serving therapy. Continuous clinical and mammographic 
follow-up is recommended for all descriptors.
© 2015 S. Karger GmbH, Freiburg
Introduction
Several authors have reported that the presence of mammo-
graphic calcifications is indicative of poor long-term clinical out-
come [1–8]. The descriptors of calcification morphology represent 
a prognostic indicator for grading [9, 10], successful first excision 
[11] and survival [1, 6, 12, 13]. Tabar et al. [1, 12] and others [6, 7, 
13] have shown that the presence of fine linear or fine linear 
branching (casting type) calcifications is a prognostic indicator for 
poorer survival. Holland et al. [14] suggested that round/punctuate 
calcifications are an indicator for unsuccessful first excision and 
recurrence.
The major progress in breast cancer survival achieved during 
the last decade is based upon adjuvant treatment of breast cancer 
[15]. Breast cancer is a heterogeneous disease as regards its gene-
expression profile, pathological and mammographic appearance, 
biological behavior and the response to treatment. Management of 
breast cancer in clinical practice has evolved with the availability 
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Summary
Introduction: In this study we evaluated mammographic, 
histological and immunohistochemical findings for mi-
crocalcification-associated breast cancer with regards to 
breast-conserving therapy, recurrence and survival rate. 
Patients and Methods: We retrospectively analyzed 99 
consecutive, non-palpable and microcalcification-associ-
ated breast cancers (94 women) that were treated surgi-
cally between January 2002 and December 2003 at a na-
tional academic breast cancer center. Calcifications were 
classified according to the Breast Imaging Reporting and 
Data System (BI-RADS). Descriptors, surgical outcome 
and histological findings were assessed. Recurrences 
and survival rates were evaluated based on medical re-
cords, standardized patient questionnaires and/or con-
tacting the physician. Results: 42 of the 99 lesions 
(42.4%) were invasive carcinomas, 57 (57.6%) were pure 
ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions 
were triple negative, and 29 (29.3%) were HER2/neu pos-
itive. Successful first excision rate was 76/99 lesions 
(76.8%). Breast conservation was achieved in 73.7% 
(73/99). 10 women showed local recurrences without 
negatively impacting survival. The recurrences included 
round/punctate, amorphous, fine pleomorphic, and fine 
linear or fine-linear branching descriptors. The breast 
cancer-specific long-term survival rate was 91/94 (96.8%) 
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and use of immunohistochemistry. However, for microcalcifica-
tion-associated breast cancers little is known about the incidence, 
distribution and impact of immunohistochemistry.
Therefore, we performed a retrospective analysis of our data-
base to assess the outcome of microcalcification-associated breast 
cancers with special focus on Breast Imaging Reporting and Data 
System (BI-RADS) descriptors of calcification morphology, histol-
ogy, and immunohistochemistry with respect to successful first 
surgery, breast-conserving surgery, recurrence and long-term sur-
vival rate.
Patients and Methods
Study Design
This retrospective cohort study included the long-term follow-up of 99 con-
secutive malignant and non-palpable lesions that contained microcalcifications 
(from 94 women) that were treated with hook-wire guided surgery between 
January 2002 and December 2003 in an academic tertiary-care institution.
Patients
The institutional review board approved this study and waived the require-
ment for informed consent. Data on pathological features, surgery, recurrence, 
and survival outcomes were gathered from our hospital database. A semi-struc-
tured questionnaire was send by mail to all women for whom a lack of recur-
rence or survival was unclear at the validation date (n = 47). 32 out of 47 women 
or their husbands answered the questionnaire by mail. The general practition-
ers of the 15 women from whom no reply to our initial questionnaire was re-
ceived were contacted either by mail or phone. Information on recurrence and 
survival was obtained for 8 of these 15 women. 4 out of remaining 7 patients 
were successfully contacted by phone and information was obtained. Thus, of 
94 women, 3 were lost to follow-up; for 6 women we lacked information on 
local/regional recurrence. The observation period was either from the time of 
first surgery until 1 January 2010 (defined as time point 1) or information 
gained later than 1 January 2010 (defined as time point 2). The last patient was 
followed up until 23 January 2012.
Mammography Reading
Patients and mammography readings were part of previous evaluations re-
lated to the positive predictive value for malignancy of suspicious descriptors of 
microcalcifications and presence of additional parenchymal findings according 
to the American College of Radiology (ACR) BI-RADS, 4th edition [16] and 
up-dated to the ACR BI-RADS 5th edition for this study [17]. Only 1 descriptor 
from each suspicious morphological class of microcalcifications was used to de-
scribe the findings in a mammogram. In the case of multiple different calcifica-
tion forms, the more suspicious category was chosen. Suspicious calcifications 
were amorphous, coarse heterogeneous, fine pleomorphic, and fine linear or 
fine-linear branching calcifications. Round/punctate calcifications were based 
on selected suspicious round/punctate calcifications that underwent histologi-
cal assessment.
Histology
Ductal carcinoma in situ (DCIS) and invasive carcinoma were considered to 
be malignant. Grading for invasive carcinoma was performed according to 
Elston and Ellis [18] and for DCIS according to the grading part of the Van 
Nuys classification [9]. If there were multiple histological findings within 1 
specimen, the most suspicious histopathology was considered the final histo-
logical result. 
Immunohistochemistry
In 2002 and 2003, estrogen receptors were assessed using monoclonal 
mouse anti-human estrogen receptor alpha clone 1D5 (Dako M 7047) at a dilu-
tion of 1: 100, progesterone receptors using monoclonal mouse anti-human 
progesterone receptor PgR 636 (Dako M 3569) at a dilution of 1: 50, and human 
epidermal growth factor receptor 2 (Her2/neu) using polyclonal rabbit anti-
human c-erB-2 oncoprotein (Dako A 0485) at a dilution of 1: 500. In 2002 and 
2003, the proliferation marker Ki-67 was not routinely assessed. For 5 lesions 
immunochemistry was either not available or not feasible due to small tumor 
size.
Therapy
Therapy was performed according to contemporary national guidelines. In 
2002 and 2003, a resection free margin greater than 5 mm was standard (today 
greater 1  mm). Successful first excision rate excludes prior diagnostic proce-
dures. Final mastectomy rate was defined as mastectomy for the initial disease 
and excludes later mastectomy for recurrence. Final mastectomy rate includes 
patients with the wish for mastectomy despite national recommendations.
Statistics
For statistical analysis, we used Excel (Excel 2000, Microsoft, Redmond, 
WA), software SPSS 22 (IBM SPSS Statistics, Armonk, NY) and STATA 12 IC 
(Stata Corp, College Station, TX). For the relationship between descriptors with 
tumor characteristics and treatment, we used a Chi2 test, Fischer Exact test or 
Freeman Halton test. For statistical analysis of recurrence and survival out-
come, the Kaplan-Meier Estimator under the consideration of Delayed-Entry 
was applied using STATA 12 IC. Thus, patients with a different entrance date 
and observation period could be observed. The association between survival/
recurrence and descriptors of microcalcifications was determined by a Cox re-
gression. Kaplan-Meier plots were generated for freedom of recurrence and 
survival. A p value below 0.05 was considered significant.
Results
BI-RADS Descriptors of Calcification Morphology 
Details of mammographic descriptors in regard to tumor char-
acteristics, surgical therapy, recurrence and survival are listed in 
table 1. 15 out 99 lesions showed fine linear or fine-linear branch-
ing calcifications with an increased risk for grade 3 DCIS (4/8; 
50.0%; p = 0.351) and HER2/neu receptors positivity (7/15; 46.7%; 
p = 0.221), and without increased risk for positive axillary lymph 
nodes (2/7 invasive carcinoma; 28.6%; p = 1.000). 
The rate of successful first excision was low for round/punc-
tate microcalcifications with 5/8 (62.5%; p = 0.383) and best for 
fine linear or fine-linear branching calcifications with 13 out of 
15 (86.7%; p = 0.509) lesions. Final mastectomy rate was signifi-
cantly higher for fine pleomorphic compared to the other de-
scriptors of calcification morphology with 17/48 (35.4% vs. 
17.6%; p = 0.045).
Immunohistochemistry 
Of the 99 lesions, 65 (65.7%) were HER2/neu negative and 29 
(29.3%) positive. In comparison to HER2/neu negative lesions, 
Her2/neu-positive lesions showed a higher rate of axillary lymph 
node positivity (62.5% vs. 21.5%; p  =  0.034), and worse grading 
(G3) of DCIS (47.6% vs. 18.8%; p = 0.027, as well as worse grading 
(G3) of the invasive component (25.0% vs. 0.0%; p = 0.028). Her2/
neu-positive lesions showed a higher unsuccessful first excision 
rate (34.5% vs. 18.5%; p = 0.090), as well as recurrence rate (18.5% 
vs. 9.1%; p = 0.369). 6 of the 99 (6.1%) lesions were triple negative. 
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Coarse  
heterogeneous 
Round/  
punctate
Amorphous Fine  
pleomorphic
Fine linear  
or fine-linear  
branching
Total
Pathology, n 2 8 26 48 15 99
DCIS, n (%) 2 (100) 4 (50.0) 13 (50.0) 30 (62.5)  8 (53.3) 57 (57.6)
Grade 1 0 (0) 2 (50.0)  4 (30.8)*  9 (30.0)  1 (12.5) 16 (28.1)
Grade 2 1 (50.0) 1 (25.0)  9 (69.2)* 10/30 (33.3)  3 (37.5) 24 (42.1)
Grade 3 1 (50.0) 1 (25.0)  0 (0)* 11 (36.7)  4 (50.0) 17 (29.8)
IC, n, (%) 0 (0) 4 (50.0) 13 (50.0) 18 (37.5)  7 (46.7) 42 (42.4)
T1 0 (0) 3 (75.0) 10 (76.9) 13 (72.2)  5 (71.4) 31 (73.8)
T 2 0 (0) 1 (25.0)  3 (23.1)  4 (22.2)  2 (28.6) 10 (23.8)
T 3 0 (0) 0 (0)  0 (0)  1 (5.6)  0 (0)  1 (2.4)
Grade 1 0 (0) 2 (50.0)  2 (15.4)  2 (11.1)  1 (14.3)  7 (16.7)
Grade 2 0 (0) 2 (50.0) 11 (84.6) 14 (77.8)  6 (85.7) 33 (78.6)
Grade 3 0 (0) 0 (0)  0 (0)  2 (11.1)  0 (0)  2 (4.8)
Nodal+ 0 (0) 0 (0)  3 (23.1)  7 (38.9)  2 (28.6) 12 (28.6)
IHC, n (%)
ER+ 1 (50.0) 6 (75.0) 19 (73.1) 35 (72.9) 13 (86.7) 74 (74.7)
PR+ 0 (0) 6 (75.0) 21 (80.8)* 25 (52.1)* 11 (73.3) 63 (63.6)*
HER2/neu+ 1 (50.0) 1 (12.5)  5 (19.2) 15 (31.3)  7 (46.7) 29 (29.3)
Triple– 0 (0) 1 (12.5)  2 (7.7)  3 (6.3)  0 (0)  6 (6.1)
Surgery, n (%)
BCT 2 (100) 6 (75.0) 22 (84.6) 31 (64.6)* 12 (80.0) 73 (73.7)
1st SER 1 (50.0) 5 (62.5) 20 (76.9) 37 (77.1) 13 (86.7) 76 (76.8)
Final mastect. 0 (0) 2 (25.0)  4 (15.4) 17 (35.4)*  3 (20.0) 26 (26.3)
Outcome, n 2 8 23 46 15 94
RR, n (%) 0 (0) 2 (25.0)  2 (8.7)  3 (6.5)  3 (20.0) 10 (10.6)
MR, n (%) 0 (0) 0 (0)  0 (0)  3 (6.5)  0 (0)  3 (3.2)
*Considered significant p<0.05.
DCIS = ductal carcinoma in situ, IC = invasive carcinoma, IHC = immunohistochemisty, ER = estrogen receptor, PR = progesterone 
receptor, + = positive, – = negative, BCT = breast-conserving therapy, 1st SER = successful first excision rate, mastect. = mastectomy, 
RR = recurrence rate, MR = mortality rate.
Table 1. Tumor 
characteristics of micro-
calcification-associated, 
non-palpable breast 
cancer
Fig. 1. Kaplan-Meier plot for recurrences.
Fig. 2. Kaplan-Meier plot for survival. 
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with breast cancer-specific death showed fine pleomorphic calcifi-
cations at the time of diagnosis. All 3 women showed nodal-posi-
tive invasive carcinoma at the time of diagnosis, none of these were 
of low grade. 
Discussion
There are conflicting results in the literature regarding the prog-
nostic value of fine linear or fine linear branching calcifications for 
survival. Several authors found an increased rate of deaths [1, 6, 12, 
13, 19] with rate between 10 and 50%, others did not [10, 20]. In 
our cohort only 15 of 99 lesions contained fine linear or fine-linear 
branching calcifications. These showed a higher rate of grade 3 
DCIS and HER2/neu positivity, yet without increased nodal posi-
tivity. James et al. [10] found that the presence of fine linear or 
fine-linear branching calcifications was not an independent prog-
nostic factor, but was closely related to histological grade. In our 
study the overall survival rate was high (93.6%). All 3 deceased 
cases showed fine pleomorphic microcalcifications on preoperative 
mammograms. 
Several authors have reported that mammographic calcifica-
tions are a prognostic indicator for residual disease at excision [14, 
21–23]. Clear surgical margins greater than 1 mm were found by 
Kurniawan et al. [24] in 79.3% of pure invasive cases, but in only 
69.9% of invasive cancer with DCIS, and 53.5% of women with 
DCIS. Thomas et al. [25] reported a successful first surgery rate of 
1,981/2,564 (77.3%) cases with successful primary breast-conserv-
ing therapy in 1,430/2,564 (55.8%) and primary mastectomy in 
551/2,564 (21.9%) cases. Their final breast-conserving rate was 
1,810/2,564 (70.6%). The successful first surgery rate of our cohort 
was 76.8% (76 out of 99 cases). Breast conservation was achieved in 
73.7% (73 of 99 cases). Evans et al. [11] found a successful first ex-
pT stage (n = 10)
pT0/Tis 5
pT1 4
pT2 1
pN stage  (n = 5)
Positive 2
Negative 3
Histology (n = 10)
DCIS 5
IC 1
IC with DCIS 4
Grade of DCIS (n = 5)
G3 5
Grade of IC (n = 5)
G1 1
G2 3
G3 1
Successful excision (n = 10)
Successful first excision 6
1 reexcision 4
Type of surgery (n = 10)
Breast-conserving therapy 8
Mastectomy 2
IHC status (n = 10)
ER+ 7
PR+ 6
Her2/neu+ 5
Triple– 1
Descriptors of calcification morphology 
(n = 10)
Coarse heterogeneous 0
Round/punctate 2
Amorphous 2
Fine pleomorphic 3
Fine linear or fine linear branching 3
Table 2. Characteris-
tics of women with 
 recurrences
pT stage 
pT1 2
pT2 1
pN stage 
Positive 3
Grade of invasive carcinoma
G2 2
G3 1
Successful excision 
Successful first excision 2
2 reexcisions 1
Type of surgery 
Breast-conserving therapy 2
Mastectomy 1
IHC status
ER+ 2
PR+ 1
Her2/neu+ 2
Triple– 1
Descriptors of calcification morphology
Fine pleomorphic 3
Table 3. Characteris-
tics of deceased women 
(n = 3)
Successful First Excision and Final Mastectomy Rate
The numbers of successful first excision and women requiring 
further surgery are listed in table  1. The successful first excision 
rate was 76.8% (76/99), breast-conserving rate 73.7% (73/99), and 
final mastectomy rate 26.3% (26/99). Successful first excision rate 
of grade 3 DCIS (64.7 %; 11/17) was lower compared to grade 1 
and 2 DCIS (80%; 32/40) (p = 0.143).
Recurrences
Details of women with recurrences are listed in table  2 and 
shown in the Kaplan-Meier plot of figure 1. A recurrence was 
found in 10 of the 94 women (10.6%). The median time to recur-
rence was 55.5 months with a range of 6–100 months. The recur-
rences in 5 of the 10 women (50%) were initially staged as pure 
DCIS, and 5 as invasive carcinoma. All 5 DCIS were grade 3. The 
recurrences concerned all descriptors of calcification morphology 
except for coarse heterogeneous (0/2).
Long-Term Survival 
Details of the 3 deceased women are listed in table 3 and illus-
trated in the Kaplan-Meier plot shown in figure 2. The 3 patients 
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cision rate for pleomorphic and fine linear or fine-linear branching 
type descriptors superior to that for round/punctate microcalcifi-
cations. In our study the successful first excision rate of round/
punctate microcalcifications was low (62.5%; 5 of 8 cases).
Kini et al. [26] found that the presence of microcalcifications on 
preoperative mammography were associated with a significantly 
increased risk of local recurrence (22% vs. 6%). In a recent study, 
Holmberg et al. [7] showed an increased risk of local recurrence for 
fine linear or fine linear branching microcalcifications. Our long-
term observation showed a limited number of recurrences (10.6%) 
for all descriptors of calcification morphology, except for coarse 
heterogeneous with no recurrence. Local recurrence occurred 
throughout the follow-up period and more than 5 years after initial 
surgery. However, recurrences did not negatively impact survival 
or freedom of metastasis. The necessity and duration of mammo-
graphic follow-up is still a matter of debate [27].
It has been postulated that triple-negative breast cancers consti-
tute 10–17% of all breast cancers [28]. Billar et al. [29] found that 
triple-negative breast cancers comprised 11.6% of the invasive 
breast cancers in their single institution database. On mammogra-
phy, triple negative breast cancers usually presented with a mass or 
with focal asymmetry, and were less associated with calcifications 
[30]. The triple negative rate of our cohort with microcalcification-
associated DCIS and invasive breast cancers was only 6.1%. Ac-
cording to the literature [31–35], in 15–25% of breast carcinomas, 
there is amplification of the HER2/neu gene, an excess of the HER2 
protein in the cancer cells and a high risk of recurrence. Ko et al. 
[30] found that, in contrast to triple negativity, HER2/neu positiv-
ity was more likely to be associated with calcifications. Microcalci-
fications are generally associated with HER2/neu positivity [8, 36, 
37]. Evans et al. [38] demonstrated significant differences in the 
mammographic feature of HER2/neu-positive and -negative dis-
ease. HER2/neu-positive DCIS more commonly showed calcifica-
tion, ductal distribution, and rod-shaped and granular type calcifi-
cation. In our study based on non-palpable microcalcification-as-
sociated specimens, the HER2/neu-positivity rate was 29.3%. Com-
pared to HER2/neu-negative disease, HER2/neu-positive disease 
was more often associated with positive axillary lymph node status, 
grade 3 DCIS, unsuccessful first surgery, and a higher rate of 
recurrence. 
Inter- and intra-observer variability apply to mammographic 
descriptors, histological grading as well as immunohistochemistry. 
Use of different grading systems and techniques is a further source 
for inter-study variability. We did not evaluate the extent of calcifi-
cations and tumor extent by histopathology. Evans et al. [11] found 
that the mammographic bi-dimensional extent is a powerful pre-
dictor of successful single therapeutic wide local excision of DCIS 
when combined with histological grade and/or calcification mor-
phology. Although in our study great care and effort was applied to 
achieve comprehensive follow-up, the follow-up was not complete 
for all women. The number of patients who died from their dis-
ease, or had recurrences, was small in this single center study, thus 
statistical significance was limited. Future data from large register 
studies will be of interest.
In this long-term follow-up study, microcalcification-associ-
ated, non-palpable breast cancers were treated with a high rate of 
breast-conserving therapy. The mortality rate was low and related 
to node-positive status at the time of diagnosis. Recurrences were 
found throughout the follow-up period. Therefore, mammography 
should be considered early and follow-up should be longer than 
5 years. 
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